The article presents the results of the study of the combination of aminosugars - glucosamine hydrochloride (GA h/ch) and N-acetylglucosamine - with quercetin (Q) called GlukvamineTM as a corrector of hepatotoxicity induced by methotrexate (MTX). The study was conducted on a model of MTX-induced liver damage in rats. GlukvamineTM was studied in the dose of 82 mg/kg with daily intragastric administration for 10 days compared to the substance GA h/ch, which was administered intragastrically at a dose of 50 mg/kg, and the substance of Q, which was administered intragastrically in the dose of 20.5 mg/kg. The efficiency of the drugs was assessed by the general condition of the animals, the values of the liver mass coefficient, the biochemical parameters of the blood serum and the histological analysis of the liver tissue. The GlukvamineTM effect on rats with MTX-induced liver damage caused an improvement of their general condition, recovery of the functional state of the liver by biochemical indicators, and the results of the histological analysis indicated a decrease in hepatotoxicity of MTX. At the same time, GlukvamineTM has statistically significantly exceeded the effect of GA h/ch and Q by most parameters. Thus, GlukvamineTM is a promising effective and safe drug for pharmacological correction of the hepatotoxicity of MTX.
Keywords: GlukvamineTM; Methotrexate; glucosamine; hepatoprotective effect; methotrexate; quercetin.